Therapeutic Intervention

• Based on the patient’s previous good response to aPCC, a prophylaxis regimen of aPCC is recommended to be self-infused 3x weekly at a dose of 75 U kg^-1
• Instead of replacing missing factor, (i.e., as with factor replacement therapy), aPCC is a bypassing agent that can achieve clot formation without the need for FVIII, ie it “bypasses” the need for FVIII

 

Cindy Leissinger, MD Professor of Medicine, Pediatrics & Pathology Chief, Section of Hematology & Medical Oncology Tulane University School of Medicine